Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Preliminary results (n=13) presented at the 20th World Conference on Lung Cancer
- 15 Oct 2018 Planned number of patients changed from 104 to 98.
- 11 Jul 2018 Planned number of patients changed from 98 to 104.